Member Contact: Glenn Gilbert
Position: Chief Executive officer
Industry: Biotech & Pharmaceuticals
Imagine being able to test for colorectal (bowel) cancer without having to collect and handle your own faeces. More people would screen for the disease, more cancers would be detected earlier and more lives would be saved.
In its initial diagnostic offering, ColoSTAT®, publicly listed medical diagnostics company, Rhythm Biosciences Limited [ASX:RHY], is developing a simple blood test for the accurate, affordable and accessible early detection of colorectal cancer, the third highest cause of cancer-related death worldwide.